JP2017507922A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507922A5
JP2017507922A5 JP2016547536A JP2016547536A JP2017507922A5 JP 2017507922 A5 JP2017507922 A5 JP 2017507922A5 JP 2016547536 A JP2016547536 A JP 2016547536A JP 2016547536 A JP2016547536 A JP 2016547536A JP 2017507922 A5 JP2017507922 A5 JP 2017507922A5
Authority
JP
Japan
Prior art keywords
antibody
agonist
igg antibody
present
allogeneic igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016547536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507922A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/012511 external-priority patent/WO2015112749A2/en
Publication of JP2017507922A publication Critical patent/JP2017507922A/ja
Publication of JP2017507922A5 publication Critical patent/JP2017507922A5/ja
Pending legal-status Critical Current

Links

JP2016547536A 2014-01-22 2015-01-22 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物 Pending JP2017507922A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461930386P 2014-01-22 2014-01-22
US61/930,386 2014-01-22
US201462066574P 2014-10-21 2014-10-21
US62/066,574 2014-10-21
PCT/US2015/012511 WO2015112749A2 (en) 2014-01-22 2015-01-22 Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy

Publications (2)

Publication Number Publication Date
JP2017507922A JP2017507922A (ja) 2017-03-23
JP2017507922A5 true JP2017507922A5 (https=) 2018-03-01

Family

ID=53682123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016547536A Pending JP2017507922A (ja) 2014-01-22 2015-01-22 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物

Country Status (8)

Country Link
US (2) US20160340439A1 (https=)
EP (1) EP3096787A4 (https=)
JP (1) JP2017507922A (https=)
KR (1) KR20160106170A (https=)
CN (1) CN106170299A (https=)
AU (1) AU2015209277B2 (https=)
CA (1) CA2937499A1 (https=)
WO (1) WO2015112749A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2994965A1 (en) * 2015-08-06 2017-02-09 Memorial Sloan-Kettering Cancer Center Methods and compositions for tumor therapy
TN2018000112A1 (en) * 2015-10-29 2019-10-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
WO2017144522A1 (en) * 2016-02-26 2017-08-31 Vib Vzw Tumor-associated dendritic cell preparations and uses thereof
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
WO2018140845A2 (en) * 2017-01-27 2018-08-02 Duke University Bi-specific antibodies to cd64 and a disease antigen
WO2018191369A1 (en) * 2017-04-12 2018-10-18 Memgen, Llc Methods of cd40 and toll like receptor immune activation
JP7342701B2 (ja) 2018-03-30 2023-09-12 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN110396498A (zh) * 2018-04-25 2019-11-01 重庆市畜牧科学院 体外活化记忆性b细胞成浆细胞的方法
JP2021532106A (ja) 2018-07-23 2021-11-25 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来ミニ細胞を含む組成物およびそれを使用する方法
CA3127997A1 (en) * 2019-01-28 2020-08-06 Amphera B.V. Pharmaceutical composition for use in the treatment of pancreatic cancer
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN110628621B (zh) * 2019-10-28 2023-12-22 合肥中科干细胞再生医学有限公司 一种获得肿瘤特异性t细胞的设备和方法
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
EP4724498A2 (en) * 2023-06-09 2026-04-15 The Regents of the University of California Methods for identifying and correcting tumor humoral immune dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU2001270134B2 (en) * 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
MXPA03003632A (es) * 2000-10-24 2003-09-10 Immunex Corp Metodo para tratamiento de tumores usando terapia de combinacion.
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20080031887A1 (en) * 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
CN101675075B (zh) * 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
CN107325182A (zh) * 2008-04-02 2017-11-07 宏观基因有限公司 HER2/neu‑特异性抗体和其使用方法
WO2010132622A2 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of California Anticd20-cpg conjugates and methods of treating b cell malignancies
BR112013002940A2 (pt) * 2010-08-13 2019-09-24 Baylor Res Institute adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
EP2718457A4 (en) * 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗

Similar Documents

Publication Publication Date Title
JP2017507922A5 (https=)
Cerundolo et al. Harnessing invariant NKT cells in vaccination strategies
Demangel et al. Interaction of dendritic cells with mycobacteria: where the action starts
Shimabukuro-Vornhagen et al. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells
Dellacherie et al. Single‐shot mesoporous silica rods scaffold for induction of humoral responses against small antigens
Houot et al. Vaccines for lymphomas: idiotype vaccines and beyond
US20110195456A1 (en) Methods and compositions for the production of monoclonal antibodies
Yu et al. Combinational immunotherapy with Allo-DRibble vaccines and anti-OX40 co-stimulation leads to generation of cross-reactive effector T cells and tumor regression
JP2017507922A (ja) 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物
JP6387156B2 (ja) 乳癌再発の予防用ワクチン
JP2014521657A (ja) 膵臓がんに対する樹状細胞（ｄｃ）ワクチン療法
Pieper et al. Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models
Van Dinther et al. Comparison of protein and peptide targeting for the development of a CD169-based vaccination strategy against melanoma
KR102578682B1 (ko) Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
JP6952603B2 (ja) クラミジア活性化ｂ細胞プラットフォーム及びその方法
CN102782123A (zh) 用于抑制肿瘤细胞增殖的改进的组合物
CN103003305A (zh) 癌症疫苗
Yang et al. Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors
Roehnisch et al. Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model
Kehry et al. B-cell activation by helper T-cell membranes
Kwak Translational development of active immunotherapy for hematologic malignancies
Thakur et al. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells
JP6811194B2 (ja) 免疫原性プレプロカルシトニンペプチド
Hollander Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma
Baio et al. Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes